Similarly, TNFAIP8 knockdown reduced the IC50 of chemotherapeutics in K562/A02 and HL60/ADR, confirming that TNFAIP8 ablation can re-sensitize AML-resistant cells to chemotherapeutics, including doxorubicin, cytarabine and idarubicin (Fig. 3d). Here, TNFAIP8 is linked to acute myeloid leukemia.